Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $218
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn maintains an Overweight rating on AbbVie (NYSE:ABBV) and raises the price target from $211 to $218.

August 12, 2024 | 5:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst Terence Flynn maintains an Overweight rating on AbbVie and raises the price target from $211 to $218.
The raised price target and maintained Overweight rating from a reputable analyst at Morgan Stanley is likely to positively impact AbbVie's stock price in the short term as it reflects confidence in the company's performance and future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100